Robert E. Hoffman was named Chief Executive Officer of CytoDyn Inc., effective October 20, 2026. As of October 28, 2026, CytoDyn Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 19, 2026, naming 1 appointment (Form 8-K, October 19, 2026).
Sell to companies like CytoDyn Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CytoDyn Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-19. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as CytoDyn Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-19 | In | Chief Executive Officer | 2026-10-20 | 8-K, 2026-10-19 |
Selling to them or working with them? See who runs CytoDyn Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CytoDyn Inc. and the records around it.
CytoDyn Inc. elsewhere on the record
- Form D filing May 2026
Watch CytoDyn Inc.
Get an email when CytoDyn Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CytoDyn Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CytoDyn Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CytoDyn Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads CytoDyn Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Robert E. Hoffman, appointed, effective 2026-10-20 (filed 2026-10-19).
New leaders reset buying decisions — get the Full Report on CytoDyn Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at CytoDyn Inc., with the record behind each one.
Find candidates like Chief Executive Officer at CytoDyn Inc.Every change, in the filing's words
Appointed: Robert E. Hoffman, Chief Executive Officer, effective 2026-10-20
("Dr. Lalezari"), the Company's Chief Executive Officer, the Board appointed Robert E. Hoffman ("Mr. Hoffman") as the Company's Chief Executive Officer effective October 20, 2026.
Tools for this story
Each opens in a new tab, filled in for CytoDyn Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.